Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines  

作　　者：Anthony T.Tan Joey Ming Er Lim Antonio Bertoletti 

机构地区：[1]Programme in Emerging Infectious Diseases,Duke-NUS Medical School,Singapore,169857,Singapore [2]Singapore Immunology Network,A*STAR,Singapore,138648,Singapore

出　　处：《Virologica Sinica》2022年第6期783-785,共3页中国病毒学（英文版）

基　　金：supported by the Singapore Ministry of Health’s National Medical Research Council MOH-000019(MOH-Sta R17Nov-0001) grant

摘　　要：How do we measure vaccine efficacy? The strictest but also easiest parameter to determine vaccine efficacy is its ability to block infection.Indeed, if a vaccine is able to block infection, this necessarily follows that it will also prevent both disease development and viral transmission. As a consequence, antibodies, specifically neutralising antibodies, have been used as the “gold standard” correlate of protection to measure SARS-CoV-2 vaccine efficacy, given their ability to block infection.

关 键 词：VACCINE INFECTION vaccines 

分 类 号：R186[医药卫生—流行病学]